OnKure Therapeutics agrees to $150.0 million private placement at $4.15 per share

OnKure Therapeutics, Inc. (Nasdaq: OKUR) agreed on March 27, 2026 to sell 26,713,636 shares of Class A common stock at $4.15 each in a private placement. It is also selling pre-funded warrants for 9,430,959 shares at $4.1499 per underlying share. The 8-K, filed March 30, 2026, puts aggregate gross proceeds at about $150.0 million before placement agent fees and offering expenses. The closing is expected on March 31, 2026, subject to customary conditions.

Who is selling the stock

Leerink Partners LLC is the lead placement agent. Evercore Group L.L.C., LifeSci Capital LLC and Oppenheimer & Co. Inc. are co-placement agents. The 8-K does not give the banks' fees and names no legal counsel for the company or the agents.

The lead investor gets a seat and a consent right

AI Biotechnology LLC, the lead investor, can name a director for as long as it keeps at least 50% of the securities it buys at closing. On March 27 the board elected Dr. Liam Ratcliffe as a Class I director, effective only if the placement closes. The 8-K says he is affiliated with the lead investor.

Until the later of 180 days after closing and the effective date of the resale registration statement, OnKure may not issue common stock or equivalents, effect a reverse stock split, or file most registration statements without AI Biotechnology's written consent. The 8-K lists exceptions but does not describe them. Executive officers and directors agreed not to sell for the same period.

The resale registration statement is due within 30 days after closing. OnKure owes liquidated damages if it misses specified filing or effectiveness deadlines. The pre-funded warrants carry a beneficial ownership limit that holders can raise or lower, up to no more than 19.99%, on 61 days' notice.

The lead drug is being set aside

The filing's most consequential statement is in Item 8.01. The company says it "is not planning to pursue further clinical development of OKI-219 independently at this time." OKI-219 is the lead product in the 2025 annual report, filed March 12, 2026.

The company's data on OKI-219 are limited. The 10-K calls its pharmacokinetic data preliminary, with a cutoff of October 28, 2024. It says 13 of 14 patients on doses of 600 mg twice daily or more remained on study, and it describes two patients on 300 mg with prolonged stable disease. The 10-K also reports that OKI-219 was well tolerated, with all reported treatment-related adverse events at grade 1, and gives no response rates for the drug. The 8-K gives enrollment counts of 38 patients in single-agent dose escalation and 33 in the fulvestrant combination, not results.

What the money is for

The company says the proceeds will fund preclinical and clinical work on its next-generation PI3Kα pan-mutant candidates, OKI-345 in breast cancer and OKI-355 in vascular anomalies, along with working capital. Investigational new drug applications for both are planned for the first half of 2027.

The 10-K shows the cost of the current programs. Net loss for 2025 was $59.5 million, up from $52.7 million in 2024. Research and development expense rose to $48.3 million from $43.8 million. Cash used in operations was $51.8 million in 2025, against $51.1 million in 2024. Year-end 2024 cash and cash equivalents were $110.8 million. The 8-K gives no cash balance for the company.

The 8-K does not give the shares outstanding before the deal, so it cannot show how much existing holders are diluted. The offering adds 26,713,636 common shares plus pre-funded warrants for 9,430,959 more.

What comes next

Dated milestones are the resale registration statement, due within 30 days after closing, the 2026 PIKture-01 data, which OnKure says it will present by the end of the year, and the first-half 2027 IND filings for the pan-mutant candidates. Those candidates have no clinical data in these filings.

Report an error

Companies in this story

OKUROnKure Therapeutics, Inc.NASDAQ · United StatesOpen the starter desk